---
title: "Domestic and foreign brokerages unanimously optimistic about FOSUN INTL, Citigroup raises target price to HKD 6.5"
description: "On August 29th, during the earnings release, FOSUN INTL's management emphasized focusing on core businesses and global layout, receiving positive evaluations from domestic and foreign brokerages. Citi"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255532659.md"
published_at: "2025-09-02T02:18:03.000Z"
---

# Domestic and foreign brokerages unanimously optimistic about FOSUN INTL, Citigroup raises target price to HKD 6.5

> On August 29th, during the earnings release, FOSUN INTL's management emphasized focusing on core businesses and global layout, receiving positive evaluations from domestic and foreign brokerages. Citigroup raised the target price to HKD 6.5 and reiterated a "Buy" rating, believing that asset exits will enhance shareholder returns. Industrial Securities also recognized FOSUN's strategic direction, pointing out the decline in financing costs and breakthroughs in core industries. The performance of FOSUN's health sector was outstanding, especially in the biopharmaceutical field

According to Zhitong Finance APP, on August 29, FOSUN INTL (00656) held its 2025 interim performance briefing. The management released clear strategic signals, emphasizing a focus on core businesses, deepening global layout, and continuously increasing innovation investment to lay a solid foundation for future development. After the performance meeting, domestic and foreign brokerages successively published research reports optimistic about FOSUN INTL, affirming its future prospects and long-term value.

Citigroup and Industrial Securities respectively reiterated their "Buy" and "Overweight" ratings, expressing optimism about FOSUN's strategy of "focusing on core business with both advances and retreats" and the positive progress in optimizing its asset structure. Previously, Citigroup resumed coverage of FOSUN INTL on July 23 and gave it a "Buy" rating. After this performance meeting, it published another research report, reaffirming the "Buy" rating and raising the target price from HKD 5.86 to HKD 6.50.

Citigroup pointed out that FOSUN is accelerating its "advances and retreats" strategy. As of June 30, 2025, the group has completed the sale of 99.743% of its stake in the German private bank HAL while retaining the asset service business HAFS. Citigroup believes that the cash inflow from asset exits will help enhance shareholder returns. The report noted that FOSUN's stock price is trading at a 72% discount to NAV, and considering the market value of listed investments in NAV, it believes there is potential for valuation recovery for FOSUN INTL, thus raising the company's target price. Industrial Securities also recognized FOSUN's continuous optimization of its asset portfolio and clear strategic direction, noting that in the first half of the year, the expansion of overseas dollar bonds, the formation of overseas syndicates, and the issuance of domestic bonds have led to a decline in the group's financing costs of over 30 basis points compared to the end of 2024.

Citigroup and Industrial Securities also pointed out that FOSUN's core industries, such as innovative pharmaceuticals, have achieved multiple breakthroughs, and the travel and tourism business Club Med has reached new highs, with steady growth in the insurance business. In the health sector, the biopharmaceutical segment has performed particularly well, with several innovative drugs from Junshi Biosciences achieving significant breakthroughs. The world's first approved anti-PD-1 monoclonal antibody H drug, Surufatinib (Hanshu), for first-line treatment of small cell lung cancer, achieved global sales revenue of RMB 597.7 million. Currently, the H drug has been successfully approved for marketing in nearly 40 countries and regions, covering nearly half of the global population. HLX43, as the world's first PD-L1 targeted ADC drug to enter Phase II clinical trials, has begun clinical research for non-small cell lung cancer, thymic cancer, and other solid tumors in regions such as China, the United States, Japan, and Australia. Another innovative drug, HLX22, has been recognized as an orphan drug by the EU for the treatment of gastric cancer, becoming the world's first anti-HER2 therapy recognized by both the EU and the United States.

Industrial Securities also pointed out that FOSUN's overseas revenue accounted for 53%, an increase of 6.6 percentage points compared to the same period last year, indicating significant results from its global business layout. Club Med's Mediterranean club achieved record global performance, with revenue reaching RMB 9.25 billion. The insurance segment also performed well, with the group's insurance business achieving revenue of RMB 20.89 billion in the first half of the year. FOSUN's Portuguese insurance overseas gross premium reached EUR 924 million, receiving an "A" rating from S&P; Dingrui Reinsurance's gross premium income reached USD 1.061 billion, a year-on-year increase of 25.1%, demonstrating strong growth momentum In addition, FOSUN INTL continues to promote innovation in the fintech sector. Its subsidiary, Xinglu Technology, launched a one-stop RWA technology platform, FinRWA Platform (FRP), and is actively promoting asset tokenization projects. FOSUN INTL Securities and Asset Management Company have completed the upgrades for License No. 1 and No. 9, respectively, and the construction of the virtual asset and RWA platform is progressing steadily.

Overall, FOSUN has gained positive outlook from domestic and foreign brokerages by focusing on advantageous industries, optimizing capital structure, and deepening globalization, with its future development potential highly anticipated by the market

### Related Stocks

- [00656.HK - FOSUN INTL](https://longbridge.com/en/quote/00656.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盘趋势｜复星国际缩量调整，主力观望背后的机会？ | 复星国际（656.HK）昨日早盘资金参与度极低，盘中跌幅虽有限，但明显保持缩量调整态势，股价连续于前期低点附近盘整。多数资金近期选择场外观望，部分投资者曾试图博短线反弹，但盘面未现有效跟风，整体氛围偏弱。MACD 等技术信号连续数日不振，反 | [Link](https://longbridge.com/en/news/275099996.md) |
| 复星旗下的浙江复星商业发展为尚盟科技增加资本 | 浙江复星商业发展有限公司，复星国际有限公司的全资子公司，已同意向浙江尚梦科技有限公司增资。该公告通过香港证券交易所的发行人信息服务发布 | [Link](https://longbridge.com/en/news/274789288.md) |
| 星展分析师上调评级后 云顶新加坡股价涨逾 3% \| 联合早报网 | 星展集团研究将云顶新加坡的评级上调至 “买入”，目标价为 0.90 元，认为通过回购或发放特别股息等资本回报计划，该股有望提升估值并释放股东价值。云顶新加坡股价上涨 3.25%，报 0.795 元。分析师指出，公司每股净现金超过 0.27  | [Link](https://longbridge.com/en/news/276314423.md) |
| 三星、海力士 “调整战略”：新存储工厂生产计划提前 | SK 海力士计划将其龙仁一期晶圆厂的试运行时间提前至明年 2-3 月，三星电子将平泽 P4 工厂的投产时间从明年一季度提前至今年四季度，生产规划前移约三个月。调整源于 AI 数据中心扩张导致供应严重短缺，主要客户需求满足率仅 60%。市场普 | [Link](https://longbridge.com/en/news/276302716.md) |
| 花旗集团表示已签署并完成了将 AO Citibank，即花旗集团之前的俄罗斯子公司，出售给 Renaissance Capital 的交易 | 2 月 18 日（路透社）- 花旗集团：已签署并完成将花旗银行（Citi 的前俄罗斯子公司）出售给复兴资本的交易；花旗集团：此次交易使花旗完全退出其在俄罗斯的业务，包括所有剩余的业务，以及大约 800 名员工；花旗集团：预计此次剥离将在 2 | [Link](https://longbridge.com/en/news/276234739.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.